Valuation: Indivior Pharmaceuticals, Inc.

Market Cap 4.57B 3.96B 3.69B 3.39B 6.41B 435B 6.48B 43.36B 17.02B 217B 17.17B 16.79B 720B P/E 2026 *
10.4x
P/E 2027 * 9.43x
Enterprise Value 4.63B 4.01B 3.73B 3.43B 6.48B 440B 6.56B 43.88B 17.22B 220B 17.37B 16.99B 729B EV / Sales 2026 *
3.48x
EV / Sales 2027 * 3.06x
Free-Float
97.99%
Yield 2026 *
-
Yield 2027 * -
1 week+5.27%
1 month+20.78%
3 months+60.36%
6 months+29.91%
Current year+20.90%
1 week 1,160
Extreme 1160
1,264
1 month 975.5
Extreme 975.5
1,264
3 years 554.83
Extreme 554.83
2,020
5 years 335
Extreme 335
2,020
Change 5-day change 1-year change 3-year change Capi.($)
+1.56%+5.27%+49.52%-20.18% 4.57B
+4.86%-3.32%+52.73%+160.26% 1,043B
+1.04%-2.99%+50.87%+52.38% 621B
+0.98%-6.49%+24.00%+66.66% 435B
+0.43%+3.62%+47.30%+38.27% 361B
+0.66%-1.07%+35.78%+39.59% 293B
-0.70%-5.84%+8.36%+10.03% 251B
+4.57%+5.21%+35.91%+67.64% 220B
+0.97%-10.23%+2.61%-45.57% 201B
-2.58%-0.73%+17.16%+67.46% 164B
Average +0.45%-3.81%+32.42%+43.65% 398.79B
Weighted average by Cap. +0.76%-3.79%+38.44%+76.05%

Financials

2026 *2027 *
Net sales 1.33B 1.15B 1.07B 986M 1.86B 126B 1.88B 12.59B 4.94B 63.14B 4.98B 4.87B 209B 1.36B 1.18B 1.1B 1.01B 1.91B 130B 1.93B 12.92B 5.07B 64.8B 5.12B 5B 215B
Net income 467M 404M 377M 347M 655M 44.41B 662M 4.43B 1.74B 22.22B 1.75B 1.72B 73.59B 503M 435M 406M 373M 704M 47.78B 712M 4.77B 1.87B 23.91B 1.89B 1.85B 79.18B
Net Debt 54.5M 47.2M 44M 40.47M 76.4M 5.18B 77.25M 517M 203M 2.59B 205M 200M 8.59B -403M -349M -326M -300M -566M -38.36B -572M -3.83B -1.5B -19.19B -1.52B -1.48B -63.56B
Logo Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
38.73USD
Average target price
49.00USD
Spread / Average Target
+26.52%

Quarterly revenue - Rate of surprise